lactic acid has been researched along with Kaposi Sarcoma in 3 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "AIDS-related Kaposi's sarcoma (AIDS-KS), the most prevalent HIV-associated malignancy, is a debilitating, potentially fatal disease." | 1.31 | Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts. ( Kang, J; Mallery, SR; Ness, GM; Pei, P; Schwendeman, SP; Zhu, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yogev, O | 1 |
| Lagos, D | 1 |
| Enver, T | 1 |
| Boshoff, C | 1 |
| Karki, R | 1 |
| Lang, SM | 1 |
| Means, RE | 1 |
| Mallery, SR | 1 |
| Pei, P | 1 |
| Kang, J | 1 |
| Zhu, G | 1 |
| Ness, GM | 1 |
| Schwendeman, SP | 1 |
3 other studies available for lactic acid and Kaposi Sarcoma
| Article | Year |
|---|---|
Kaposi's sarcoma herpesvirus microRNAs induce metabolic transformation of infected cells.
Topics: Aerobiosis; Blotting, Western; Bone Neoplasms; Cell Proliferation; Endothelial Cells; Endothelium, V | 2014 |
The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation.
Topics: Cell Line, Tumor; Cell Proliferation; Down-Regulation; Endocytosis; Glucose; Herpesvirus 8, Human; H | 2011 |
Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts.
Topics: Acquired Immunodeficiency Syndrome; Animals; Cattle; Delayed-Action Preparations; Disease Models, An | 2000 |